catridecacog + placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inflammation
Conditions
Inflammation, Ulcerative Colitis
Trial Timeline
Oct 1, 2012 → Jul 1, 2013
NCT ID
NCT01706159About catridecacog + placebo
catridecacog + placebo is a phase 2 stage product being developed by Novo Nordisk for Inflammation. The current trial status is terminated. This product is registered under clinical trial identifier NCT01706159. Target conditions include Inflammation, Ulcerative Colitis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01706159 | Phase 2 | Terminated |
| NCT02239146 | Phase 1 | Completed |
| NCT01848002 | Phase 1 | Completed |
| NCT01847989 | Phase 1 | Completed |
Competing Products
20 competing products in Inflammation